1. Home
  2. COGT vs BHRB Comparison

COGT vs BHRB Comparison

Compare COGT & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • BHRB
  • Stock Information
  • Founded
  • COGT 2014
  • BHRB 1852
  • Country
  • COGT United States
  • BHRB United States
  • Employees
  • COGT N/A
  • BHRB N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • BHRB Major Banks
  • Sector
  • COGT Health Care
  • BHRB Finance
  • Exchange
  • COGT Nasdaq
  • BHRB Nasdaq
  • Market Cap
  • COGT 1.1B
  • BHRB 924.9M
  • IPO Year
  • COGT 2018
  • BHRB N/A
  • Fundamental
  • Price
  • COGT $12.62
  • BHRB $61.90
  • Analyst Decision
  • COGT Strong Buy
  • BHRB Strong Buy
  • Analyst Count
  • COGT 11
  • BHRB 3
  • Target Price
  • COGT $21.20
  • BHRB $71.67
  • AVG Volume (30 Days)
  • COGT 1.5M
  • BHRB 42.2K
  • Earning Date
  • COGT 11-11-2025
  • BHRB 10-24-2025
  • Dividend Yield
  • COGT N/A
  • BHRB 3.47%
  • EPS Growth
  • COGT N/A
  • BHRB N/A
  • EPS
  • COGT N/A
  • BHRB 6.89
  • Revenue
  • COGT N/A
  • BHRB $330,001,000.00
  • Revenue This Year
  • COGT N/A
  • BHRB $51.44
  • Revenue Next Year
  • COGT N/A
  • BHRB $3.58
  • P/E Ratio
  • COGT N/A
  • BHRB $9.20
  • Revenue Growth
  • COGT N/A
  • BHRB 164.69
  • 52 Week Low
  • COGT $3.72
  • BHRB $47.57
  • 52 Week High
  • COGT $13.50
  • BHRB $75.32
  • Technical
  • Relative Strength Index (RSI)
  • COGT 56.50
  • BHRB 50.30
  • Support Level
  • COGT $12.31
  • BHRB $60.69
  • Resistance Level
  • COGT $12.86
  • BHRB $64.02
  • Average True Range (ATR)
  • COGT 0.48
  • BHRB 1.24
  • MACD
  • COGT -0.08
  • BHRB -0.21
  • Stochastic Oscillator
  • COGT 46.01
  • BHRB 31.35

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About BHRB Burke & Herbert Financial Services Corp.

Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.

Share on Social Networks: